1. Food and Drug Administration. (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labelling claims.
http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
.
2. Schandelmaier, S., Conen, K., von Elm, E., You, J. J., Blumle, A., Tomonaga, Y., et al. (2015). Planning and reporting of quality-of-life outcomes in cancer trials. The Annals of Oncology, 26(9), 1966–1973.
3. Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. The Lancet, 374(9683), 86–89.
4. Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., et al. (2014). Reducing waste from incomplete or unusable reports of biomedical research. The Lancet, 383(9913), 267–276.
5. Australian New Zealand Clinical Trials Registry. (2018). Statistics to the end of January 2018.
http://www.anzctr.org.au/docs/Monthly%20Website%20Reporting_Statistics.pdf?t=139
.